PETERS, A. Safety and tolerability of Bruton’s tyrosine kinase inhibitors in the treatment of Waldenström macroglobulinemia. Canadian Hematology Today, Toronto, Canada, v. 1, n. S06, 2022. DOI: 10.58931/cht.2022.1S0628. Disponível em: https://canadianhematologytoday.com/article/view/28. Acesso em: 21 dec. 2024.